Combining a rhesus cytomegalovirus/SIV vaccine with neutralizing antibody to protect against SIV challenge in rhesus macaques

  1. Jessica Coppola
  2. Mara Parren
  3. Raiza Bastidas
  4. Karen Saye
  5. Jacqueline Malvin
  6. Joseph G. Jardine
  7. Roxanne M. Gilbride
  8. Sohita Ojha
  9. Shana Feltham
  10. David Morrow
  11. Aaron Barber-Axthelm
  12. Rachele Bochart
  13. Randy Fast
  14. Kelli Oswald
  15. Rebecca Shoemaker
  16. JeJrey D. Lifson
  17. Louis J. Picker
  18. Dennis R. Burton
  19. Scott G. Hansen
0 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

A vaccine is widely regarded as necessary for the control of the HIV pandemic and eventual eradication of AIDS. Neutralizing antibodies and MHC-E-restricted CD8+ T cells have both been shown capable of vaccine protection against the simian counterpart of HIV, SIV, in rhesus macaques. Here we provide preliminary evidence that combining these orthogonal antiviral mechanisms can provide increased protection against SIV challenge such that replication arrest observed following vaccination with a rhesus cytomegalovirus (RhCMV/SIV)-based vaccine was enhanced in the presence of passively administered incompletely protective levels of neutralizing antibody. The report invites studies involving larger cohorts of macaques and alternate routes of providing neutralizing antibody.

Related articles

Related articles are currently not available for this article.